Tobias Weber1, Benedikt Bötticher1, Walter Mier2, Max Sauter2,3, Susanne Krämer2, Karin Leotta2, Armin Keller1, Anne Schlegelmilch1, Ludger Grosse-Hovest4, Dirk Jäger1, Uwe Haberkorn2,3, Michaela A E Arndt1,5, Jürgen Krauss6. 1. Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany. 2. Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany. 3. Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Department of Immunology, University of Tübingen, Tübingen, Germany. 5. Immunotherapy Program, National Center for Tumor Diseases, German Cancer Research Center (DKFZ), Heidelberg, Germany. 6. Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany. juergen.krauss@nct-heidelberg.de.
Abstract
PURPOSE: Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin's lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitter (177)Lu. Both RICs were evaluated as single agents in a human Burkitt's lymphoma xenograft mouse model. To increase the therapeutic efficacy of the anti-CD22 RIC, combination therapy with unlabelled anti-CD20 rituximab was explored. METHODS: The binding activity of CHX-A″-DTPA-conjugated antibodies to target cells was analysed by flow cytometry. To assess tumour targeting of (177)Lu-labelled antibodies, in vivo biodistribution experiments were performed. For radioimmunotherapy (RIT) studies, non-obese diabetic recombination activating gene-1 (NOD-Rag1 (null) ) interleukin-2 receptor common gamma chain (IL2rγ (null) ) null mice (NRG mice) were xenografted subcutaneously with Raji Burkitt's lymphoma cells. (177)Lu-conjugated antibodies were administered at a single dose of 9.5 MBq per mouse. For dual-targeted therapy, rituximab was injected at weekly intervals (0.5 - 1.0 mg). Tumour accumulation of RICs was monitored by planar scintigraphy. RESULTS: Conjugation of CHX-A"-DTPA resulted in highly stable RICs with excellent antigen-binding properties. Biodistribution experiments revealed higher tumour uptake of the (177)Lu-labelled anti-CD22 IgG than of (177)Lu-labelled rituximab. Treatment with (177)Lu-conjugated huRFB4 resulted in increased tumour growth inhibition and significantly longer survival than treatment with (177)Lu-conjugated rituximab. The therapeutic efficacy of the anti-CD22 RIC could be markedly enhanced by combination with unlabelled rituximab. CONCLUSION: These findings suggest that dual targeting with (177)Lu-based CD22-specific RIT in combination with rituximab is a promising new treatment option for refractory B-NHL.
PURPOSE: Dual-targeted therapy has been shown to be a promising treatment option in recurrent and/or refractory B-cell non-Hodgkin's lymphoma (B-NHL). We generated radioimmunoconjugates (RICs) comprising either a novel humanized anti-CD22 monoclonal antibody, huRFB4, or rituximab, and the low-energy β-emitter (177)Lu. Both RICs were evaluated as single agents in a humanBurkitt's lymphoma xenograft mouse model. To increase the therapeutic efficacy of the anti-CD22 RIC, combination therapy with unlabelled anti-CD20rituximab was explored. METHODS: The binding activity of CHX-A″-DTPA-conjugated antibodies to target cells was analysed by flow cytometry. To assess tumour targeting of (177)Lu-labelled antibodies, in vivo biodistribution experiments were performed. For radioimmunotherapy (RIT) studies, non-obese diabetic recombination activating gene-1 (NOD-Rag1 (null) ) interleukin-2 receptor common gamma chain (IL2rγ (null) ) null mice (NRG mice) were xenografted subcutaneously with Raji Burkitt's lymphoma cells. (177)Lu-conjugated antibodies were administered at a single dose of 9.5 MBq per mouse. For dual-targeted therapy, rituximab was injected at weekly intervals (0.5 - 1.0 mg). Tumour accumulation of RICs was monitored by planar scintigraphy. RESULTS: Conjugation of CHX-A"-DTPA resulted in highly stable RICs with excellent antigen-binding properties. Biodistribution experiments revealed higher tumour uptake of the (177)Lu-labelled anti-CD22 IgG than of (177)Lu-labelled rituximab. Treatment with (177)Lu-conjugated huRFB4 resulted in increased tumour growth inhibition and significantly longer survival than treatment with (177)Lu-conjugated rituximab. The therapeutic efficacy of the anti-CD22 RIC could be markedly enhanced by combination with unlabelled rituximab. CONCLUSION: These findings suggest that dual targeting with (177)Lu-based CD22-specific RIT in combination with rituximab is a promising new treatment option for refractory B-NHL.
Authors: T Stokke; E Galteland; H Holte; L Smedshammer; Z Suo; E B Smeland; A L Børresen-Dale; P DeAngelis; H B Steen Journal: Int J Cancer Date: 2000-07-20 Impact factor: 7.396
Authors: Thomas E Witzig; Michael B Tomblyn; Jamal G Misleh; Ebenezer A Kio; Robert M Sharkey; William A Wegener; David M Goldenberg Journal: Haematologica Date: 2014-08-22 Impact factor: 9.941
Authors: Franck Morschhauser; Françoise Kraeber-Bodéré; William A Wegener; Jean-Luc Harousseau; Marie-Odile Petillon; Damien Huglo; Lorenz H Trümper; Johannes Meller; Michael Pfreundschuh; Carl-Martin Kirsch; Ralph Naumann; Joachim Kropp; Heather Horne; Nick Teoh; Steven Le Gouill; Caroline Bodet-Milin; Jean-Francois Chatal; David M Goldenberg Journal: J Clin Oncol Date: 2010-07-12 Impact factor: 44.544
Authors: R M Sharkey; T M Behr; M J Mattes; R Stein; G L Griffiths; L B Shih; H J Hansen; R D Blumenthal; R M Dunn; M E Juweid; D M Goldenberg Journal: Cancer Immunol Immunother Date: 1997-05 Impact factor: 6.968
Authors: Daniel A Vallera; Martin W Brechbiel; Linda J Burns; Angela Panoskaltsis-Mortari; Katie E Dusenbery; Dennis R Clohisy; Ellen S Vitetta Journal: Clin Cancer Res Date: 2005-11-01 Impact factor: 12.531
Authors: P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier Journal: J Clin Oncol Date: 2005-05-02 Impact factor: 44.544
Authors: Rosana B Michel; Philip M Andrews; Adriane V Rosario; David M Goldenberg; M Jules Mattes Journal: Nucl Med Biol Date: 2005-04 Impact factor: 2.408
Authors: O W Press; M Corcoran; K Subbiah; D K Hamlin; D S Wilbur; T Johnson; L Theodore; E Yau; R Mallett; D L Meyer; D Axworthy Journal: Blood Date: 2001-10-15 Impact factor: 22.113
Authors: Jostein Dahle; Jørgen Borrebaek; Thora J Jonasdottir; Anne Kristine Hjelmerud; Katrine B Melhus; Øyvind S Bruland; Oliver W Press; Roy H Larsen Journal: Blood Date: 2007-05-29 Impact factor: 22.113
Authors: Marion M Malenge; Sebastian Patzke; Anne H Ree; Trond Stokke; Peter Ceuppens; Brian Middleton; Jostein Dahle; Ada H V Repetto-Llamazares Journal: J Nucl Med Date: 2020-04-03 Impact factor: 10.057